About this trial
The objective of this research is to assess the efficacy of oral metformin in mitigating the aging process in middle-aged and elderly males, to pinpoint sensitive indicators of human senescence, and to offer innovative frameworks and scientific insights for pharmaceutical interventions in aging.
Eligibility criteria
Qualifiers
Male
Age 55-65; 18-28;
Able to understand and execute instructions;
After reading the consent form, be able to answer questions about the study and demonstrate understanding of the protocol;
Disqualifiers
Severe chronic or acute disease: cancer, clinically significant congestive heart failure, chronic obstructive pulmonary disease (COPD), previous or new-onset diabetes, inflammatory state, serum creatinine >1.5 mg/dl , active liver disease, History of metabolic acidosis, poorly controlled hypertension, epilepsy, recent (within 3 months) cardiovascular events (MI, PTCA, CABG, stroke), severe renal insufficiency, inflammatory bowel disease, persistent glucocorticoids Treatment; neurological diseases such as dementia, AD, PD, etc.; infectious diseases such as HIV, hepatitis, tuberculosis, etc.; severe autoimmune diseases;
BMI<18.5 or BMI>30;
Persistent alcohol or drug abuse;
Treatment with drugs known to affect glucose metabolism (other diabetes drugs, systemic glucocorticoids, niacin);
Trial design
Treatments tested in this trial
- Metformin Hydrochloride tablet
- Placebo
Treatment groups
Sponsors and collaborators
Xuanwu Hospital, Beijing
Lead sponsor
Institute of Zoology, Chinese Academy of Sciences
Collaborator
Beijing Institute of Genomics, Chinese Academy of Sciences
Collaborator
Merck Serono Co., Ltd., China
Collaborator